ID CLB HC.PH.BIO.CLB
Develops drugs, biologics or cell and gene therapies with no approved product on the market (no revenue, or milestones only); such a developer is here, not in contract research.
Sector, group and industry above this class, as placed in the current release. The sector and the industry link to their companies.
Companies whose primary class this is. The sector and industry pages and the screener count them the same way.
| Company | Ticker | Country | Market cap | Filings |
|---|---|---|---|---|
| Bolt Biotherapeutics, Inc. | BOLT | United States of America | $7.78M | 296 |
| Biosergen AB | BIOSGN | Sweden | $8.80M | 227 |
| Acurx Pharmaceuticals, Inc. | ACXP | United States of America | $7.22M | 249 |
| Sonnet BioTherapeutics Holdings, Inc. | SONN | United States of America | $8.60M | 1,133 |
| Nextage Therapeutics Ltd. | NXTG | Israel | $8.34M | 3,010 |
| NuCana plc | NCNA | United Kingdom | $5.79M | 280 |
| Sunshine Biopharma Inc. | SBFM | United States of America | $4.44M | 409 |
| Processa Pharmaceuticals, Inc. | PCSA | United States of America | $6.93M | 706 |
| Transcode Therapeutics, Inc. | RNAZ | United States of America | $5.32M | 319 |
| Pure Biologics S.A. | PUR | Poland | $7.12M | 616 |
| Aprea Therapeutics, Inc. | APRE | United States of America | $7.82M | 444 |
| Tessera Defense & Homeland Security Inc. | HLSQ | United States of America | $7.79M | 914 |
| Niki BioSolutions, Inc. | NIKI | United States of America | $7.76M | 338 |
| OncoZenge AB | ONCOZ | Sweden | $7.71M | 320 |
| Pulmatrix, Inc. | PULM | United States of America | $7.71M | 641 |
| PILA PHARMA AB | PILA | Sweden | $7.55M | 233 |
| Spago Nanomedical AB | SPAGO | Sweden | $7.43M | 636 |
| PharmaCyte Biotech, Inc. | PMCB | United States of America | $7.73M | 469 |
| Zelluna ASA | ULTI | Norway | $7.37M | 605 |
| Lakewood-Amedex Biotherapeutics Inc. | LABT | United States of America | $7.23M | 36 |
| Silo Pharma, Inc. | SILO | United States of America | $5.39M | 373 |
| SYNLOGIC, INC. | SYBX | United States of America | $8.07M | 626 |
| CollPlant Biotechnologies Ltd | CLGN | United States of America | $6.84M | 2,460 |
| Liminatus Pharma, Inc. | LIMN | United States of America | $7.21M | 102 |
| NUFORMIX PLC | NFX | United Kingdom | $5.75M | 294 |
| Can-Fite BioPharma Ltd. | CANF | Israel | $7.99M | 3,875 |
| Addex Therapeutics Ltd. | ADXN | Switzerland | $6.57M | 858 |
| FF EAI Robotics Ecosystem Inc. | AIXC | United States of America | $6.53M | 644 |
| Alaunos Therapeutics, Inc. | TCRT | United States of America | $5.28M | 1,213 |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | CELZ | United States of America | $5.70M | 405 |
| PURPLE BIOTECH LTD. | PPBT | United States of America | $1.45M | 576 |
| Xenetic Biosciences, Inc. | XBIO | United States of America | $6.27M | 483 |
| FibroBiologics, Inc. | FBLG | United States of America | $4.78M | 235 |
| XTL Biopharmaceuticals Ltd. | XTLB | Israel | $6.28M | 1,952 |
| Purple Biotech Ltd. | PPBT | Israel | $5.95M | 2,677 |
| MUSTANG BIO, INC. | MBIO | United States of America | $5.08M | 403 |
| Quantum Genomics | ALQGC | France | $5.82M | 351 |
| Ernexa Therapeutics Inc. | ERNA | United States of America | $7.21M | 1,433 |
| BioRestorative Therapies, Inc. | BRTX | United States of America | $5.72M | 764 |
| PSYENCE BIOMEDICAL LTD. | PBM | Canada | $8.05M | 166 |
| THERACRYF PLC | TCF | United Kingdom | $5.59M | 374 |
| ARTELO BIOSCIENCES, INC. | ARTL | United States of America | $4.98M | 456 |
| N4 PHARMA PLC | N4P | United Kingdom | $5.27M | 826 |
| Combigene AB | COMBI | Sweden | $5.23M | 884 |
| Aptevo Therapeutics Inc. | APVO | United States of America | $5.91M | 722 |
| Decoy Therapeutics Inc. | DCOY | United States of America | $4.92M | 733 |
| Quince Therapeutics, Inc. | QNCX | United States of America | $16.85M | 472 |
| Aspire Biopharma Holdings, Inc. | ASBP | United States of America | $4.59M | 216 |
| REVELATION BIOSCIENCES, INC. | REVB | United States of America | $3.93M | 382 |
| MetaVia Inc. | MTVA | United States of America | $8.83M | 634 |
Other names for this activity, and where neighboring activities go instead.
preclinicaldrug developer
Research-led company whose approved medicines, which it discovered, are in one or two therapeutic areas; it moves to Branded Prescription Drugs only after two consecutive annual reports with approved products in three or more.
https://financialfilings.com/oics/CLB/
This page is keyed by the class ID CLB. IDs are assigned in v0.3 and freeze at v1.0; from then on an ID is never renamed or reused, and if the class moves in the tree, its ID and this URL stay the same.
Sign in or create a free account - no password needed.
By continuing, you agree to our Terms and Privacy Policy.